PHP41 Risk Management in Iranian Pharmaceutical Companies to Ensure Accessibility and Quality of Medicines

Abstract

fasalazine, Multi-Matrix System mesalamine [MMX], balsalazide disodium, mesalamine delayed release [MDR]) during 2007-2011. Patients were continuously enrolled in the 6-month pre-and 12-month post-initiation period. 5-ASA treatment persistence and adherence according to the initial prescription filled (index medication) were compared. Persistence was defined as the duration between initiation and discontinuation of therapy with a permissible gap Ͻ60 days, and analyzed using Kaplan-Meier survival analysis. Persistence rates at month 12 were calculated. Adherence was measured by medication possession ratio (MPR) for index drug, and proportion of days covered (PDC) for any 5-ASA. Analysis of covariance was used to compare MPR and PDC across index medication. Covariates included age, gender, insurance, residential region, comorbidities at index date, and use of immunosuppressive/biologic agents, rectal form of 5-ASA and access to specialist care post 12-month index date. RESULTS: A total of 5245 patients met selection criteria, 59% were on MDR, 17% MMX, 13% sulfasalazine, and 11% balsalazide. The median persistence days ranged from 151 [sulfasalazine] to 221 [MMX] days, Pϭ0.001). Persistence rates at month 12 was highest for MMX (28%) compared to other 5-ASAs (24% MDR, 23% balsalazide, and 20% sulfasalazine, respectively, logrank PϽ0.001). Mean adjusted MPR/PDC Ϯ standard error was significantly higher in the patients on MMX (0.48Ϯ0.02/0.53Ϯ0.02) than that of patients on other 5-ASAs (0.43Ϯ0.

Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods

“…In addition, medicine is a highly regulated good and under the controls and restrictions of public regulatory authorities [ 2 , 11 , 12 ]. To overcome supply chain vulnerabilities, it is essential to identify and prioritize obstacles to create best practice for proper configuration and adaptability in pharmaceutical industry [ 13 , 14 ].…”

Pharmaceutical supply chain risks: a systematic review

“…SCRM attempts to minimize supply chain vulnerability and uncertainties through mitigation plans [ 23 ]. Therefore it is essential to identify, assess and prioritize all risks to reduce and control the probability and impacts of unfortunate events [ 24 ]. It is aimed to managing the risks in a complex and dynamic supply and demand networks [ 25 ].…”

Securing pharmaceutical supply chain using digital drug serialization

“…For supply chain management to accomplish the aforementioned goals, supply chain risk management (SCRM) is a critical and integral component [25]. Therefore, to lower and limit the likelihood of unfavorable events and their effects, it is crucial to identify, evaluate, and prioritize all risks [26]. Its goal is to manage the risks of intricate and changing supply and demand networks [27].…”